Clinical trials: Vaccinia
Neonate, Maternal Transmission
Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC
This Phase 3 open-label study aims to assess the safety and immune response of the MVA-BN mpox vaccine when administered subcutaneously to pregnant and postpartum women in the Democratic Republic of the Congo (DRC), a population…
- Conditions
- Neonate, Maternal Transmission, Mpox, Vaccination
- Trial name
- PregInPoxVac (NCT06844500)
- Testing
- MVA-BN standard regimen, MVA-BN standard regimen (Administered as PEP)
- Where
- Democratic Republic of the Congo
- Volunteers
- 359 people, healthy volunteers welcome
- Sponsor
- Jean-Pierre Van geertruyden
Cytomegaloviral Infection, Hematopoietic Cell Transplant Recipient
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant
This phase I/II trial studies the side effects and best dose of multi-antigen cytomegalovirus (CMV)-modified vaccinia ankara vaccine and to see how well it works in treating pediatric patients with positive cytomegalovirus who…
- Trial name
- NCT03354728
- Testing
- Laboratory Biomarker Analysis, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- City of Hope Medical Center
Atopic Dermatitis
Identifying Genetic Determinants of Eczema Herpeticum and Other Viral Infections in Individuals With Atopic Dermatitis
People with atopic dermatitis (AD), or eczema, are susceptible to skin infections and inflammations. Some individuals with AD develop a condition known as eczema herpeticum (EH) following exposure to the herpes simplex virus…
- Trial name
- Genetics (NCT00515047)
- Where
- 7 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by recurrent viral skin infections. Recent studies have demonstrated that the skin of people with AD my have decreased antimicrobial peptide (AMP)…
- Trial name
- NCT00407069
- Where
- United States
- Volunteers
- 286 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Neuroblastoma, Rhabdomyosarcoma
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
This is a Phase I, open-label, dose-escalation trial of JX-594 (Pexa-Vec) in pediatric patients with advanced/metastatic, unresectable solid tumors refractory to standard therapy and/or the patient does not tolerate standard…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Wilm's Tumor
- Trial name
- NCT01169584
- Testing
- Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Jennerex Biotherapeutics
Myocarditis, Pericarditis
ACAM2000® Myopericarditis Registry
The purpose of this registry is to study the natural history of vaccination-related myocarditis and pericarditis and to assess possible risk factors for these conditions.
- Trial name
- NCT01395082
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Vaccinia
Evaluation of Healthcare Workers Knowledge Regarding Their Vaccination Status at Melun Hospital
The goal of this observational study is to learn about the rate the of knowledge of own vaccination status among healthcare workers working at Groupe Hospitalier Sud Ile de France.
- Trial name
- STATUVAX-PRO (NCT06650722)
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Groupe Hospitalier Sud Ile-de-France
Smallpox
Safety Surveillance Study of ACAM2000® Vaccinia Vaccine
This is an enhanced safety surveillance study that will occur within the military Service Member population. Primary Objective: To evaluate the rates of suspected, probable, and confirmed myocarditis and/or pericarditis in…
- Trial name
- NCT00927719
- Testing
- ACAM2000® smallpox vaccine
- Where
- 4 sites in United States
- Volunteers
- 897,227 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Mpox (Monkeypox), Vaccination
Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC
This Phase 3 double-blinded, randomized study aims to evaluate the safety and immunogenicity of the two-dose MVA-BN mpox vaccine regimen, administered subcutaneously, in infants and children aged 4 to 24 months in the Democratic…
- Conditions
- Mpox (Monkeypox), Vaccination, Immunogenicity, Safety
- Trial name
- PregInPoxVac (NCT06844487)
- Testing
- MVA-BN standard regimen, MVA-BN half-dose regimen
- Where
- Democratic Republic of the Congo
- Volunteers
- 344 people, healthy volunteers welcome
- Sponsor
- Jean-Pierre Van geertruyden
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Trial name
- NCT00019734
- Testing
- aldesleukin, fowlpox virus vaccine vector, vaccinia-tyrosinase vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Healthy
Phase I Trial of Smallpox Vaccine
This study will test the safety of an experimental vaccine called Modified Vaccinia Virus Ankara (MVA) for use against the smallpox virus.
- Trial name
- NCT00046397
- Testing
- Modified Vaccinia Virus Ankara TBC-M
- Where
- United States
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus Disease 2019, Vaccinia
Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In Service
comparison of general characteristics of patients diagnosed COVID-19 positive followed In service
- Conditions
- Coronavirus Disease 2019, Vaccinia, Symptoms and Signs
- Trial name
- COVID-19 (NCT05092568)
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people
- Sponsor
- Saglik Bilimleri Universitesi
Melanoma (Skin)
Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00054535
- Testing
- aldesleukin, recombinant fowlpox-tyrosinase vaccine, vaccinia-tyrosinase vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Prostatic Neoplasms
A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate
This trial will evaluate, in patients with metastatic prostate cancer, the tolerability, toxicities, efficacy, and immunologic effects of repeated vaccinations with a recombinant vaccinia virus that contains the Prostate Specific…
- Trial name
- NCT00001382
- Testing
- PROSTVAC
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Complication of Smallpox Vaccination
VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection
This is a post-marketing study to verify the clinical benefits of VIGIV [CNJ-016, Vaccinia Immune Globulin Intravenous (Human), sterile solution] in the resolution of complications resulting from smallpox vaccination in eligible…
- Trial name
- NCT01374984
- Testing
- VIGIV
- Volunteers
- 100 people
- Sponsor
- Emergent BioSolutions
Healthy Volunteer
A Single-volunteer Study of Immune Response Following OTS-412 Vaccinia Virus Systemic Injection(Self-experiment)
Following oncolytic virus (OV) administration, the host immune response is initiated immediately and evolves dynamically. However, in clinical OV therapy, it is virtually impossible to capture these immune events in real time.
- Trial name
- NCT07302945
- Testing
- OTS-412
- Where
- South Korea
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Bionoxx Inc.
Smallpox
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
Primary Objectives: To compare the rates of myopericarditis (subclinical, suspected, probable, or confirmed) in deploying military subjects who received ACAM2000® vaccine to rates among subjects positioned to deploy who would be…
- Trial name
- NCT00928577
- Where
- 4 sites in United States
- Volunteers
- 14,108 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Healthy, Communicable Diseases
Vaccinia Immune Globulin in Treating or Preventing Vaccinal Infection
The purpose of this study is to follow responses to treatment with vaccinia immune globulin (VIG) for safety and clinical benefit [during HIV vaccine research].
- Trial name
- NCT00006630
- Testing
- Vaccinia Immune Globulin (Human)
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Double-stranded DNA Virus
Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses
This was a multicenter, open-label study of oral brincidofovir (BCV) treatment of serious disease or conditions caused by double-stranded DNA (dsDNA) virus(es).
- Trial name
- NCT01143181
- Testing
- Brincidofovir
- Where
- 37 sites in United States
- Volunteers
- 210 people
- Sponsor
- Jazz Pharmaceuticals
Hemorrhagic Fever, Ebola
Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
The purpose of this study is to assess the safety, tolerability and immunogenicity of three heterologous prime-boost regimens for Ebola vaccines Ad26.ZEBOV and MVA-BN-Filo.
- Trial name
- NCT02564523
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 1,075 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.